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Abstract
Introduction Arthroscopy is a minimally invasive technique for
retrieving synovial biopsies in rheumatology during the past 20
years. Vital for its use is continual evaluation of its safety and
efficacy. Important for sampling is the fact of intraarticular
variation for synovial markers. For microscopic measurements
scoring systems have been developed and validated, but for
macroscopic evaluations there is a need for further
comprehensive description and validation of equivalent scoring
systems.
Methods We studied the complication rate and yield of
arthroscopies performed at our clinic between 1998 and 2005.
We also created and evaluated a macroscopic score set of
instructions for synovitis.
Results Of 408 procedures, we had two major and one minor
complication; two haemarthrosis and one wound infection,
respectively. Pain was most often not a problem, but 12
procedures had to be prematurely ended due to pain. Yield of
biopsies adequate for histology were 83% over all, 94% for
knee joints and 34% for smaller joints. Video printer
photographs of synovium taken during arthroscopy were jointly
and individually reviewed by seven raters in several settings, and
intra and inter rater variation was calculated. A macroscopic
synovial scoring system for arthroscopy was created (Macro-
score), based upon hypertrophy, vascularity and global
synovitis. These written instructions were evaluated by five
control-raters, and when evaluated individual parameters were
without greater intra or inter rater variability, indicating that the
score is reliable and easy to use.
Conclusions In our hands rheumatologic arthroscopy is a safe
method with very few complications. For knee joints it is a
reliable method to retrieve representative tissue in clinical
longitudinal studies. We also created an easy to use
macroscopic score, that needs to be validated against other
methodologies. We hope it will be of value in further developing
international standards in this area.
Introduction
Diseases causing chronic inflammation in joints are common
and often debilitating conditions. The synovial membrane (SM)
is the primary target organ for the immune system in many
chronic arthritides, and particularly in rheumatoid arthritis (RA)
where a pannus of cells is formed, eroding cartilage and bone.
Consequently, it is to be expected that investigations of the
SM will provide clues to the pathogenesis of disease and
effect of therapy. A number of studies have shown that the
inflammatory changes in the synovium correlate with clinical
[1-6], as well as radiological [7-10], outcomes.
Effects of different treatments [11-32] on these patterns have
been studied and efforts have been made to investigate
whether synovial histology markers could be used to evaluate
the effect of a drug with some success [27,30,32]. Sampling
of the synovial membrane has also been used as a 'proof of
concept' prior to [33] or early on in clinical trials [34] of new
drugs. Importantly, more recent studies have also found pre-
dictive markers of clinical effect [28,31,35]; however, more
work needs to be conducted before we have simple markers
enabling physicians to individually tailor medication. So far
these markers are exclusively present in the synovium, the tar-
get organ of the inflammation, requiring surgical sampling of
tissue.
Arthroscopy is a minimally invasive technique, traditionally
used by orthopaedic surgeons, which has evolved as a
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research instrument in rheumatology to permit retrieval of SM
during the past 20 years. Vital for its use is continual evaluation
of its safety and efficacy, and the fact that there is intra-articu-
lar variation for synovial markers is important for sampling [36].
For microscopic measurements scoring systems have been
developed and validated [37,38], but for macroscopic evalua-
tions there is a need for further comprehensive description and
validation of equivalent scoring systems.
In this report we aim to document our own experience with
arthroscopy [36,39-51] describing the method, its safety and
evaluating a macroscopic scoring system of synovitis devel-
oped by us.
Materials and methods
Patients
For seven years, from September 1999 to September 2005,
234 patients were recruited from the rheumatology clinic at
the Karolinska University Hospital, and three patients from pri-
vate rheumatologists. For research purposes, 210 patients
were recruited, and 27 patients were recruited for clinical rou-
tine examination. Except for 10 healthy individuals, all patients
had clinically active arthritis or joint pain at the time of arthros-
copy. Indications for arthroscopy in clinical routine practice
were mainly arthritis of unknown origin (mainly monoarthritis)
or arthritis in singular joints without satisfying response to ther-
apy. Projects for research purposes were primarily aimed at
learning more about the early course of disease and the
molecular mode of action of different anti-rheumatic treat-
ments. Contraindications for arthroscopy were age below 18
years, prosthesis, clotting or bleeding deficiency, known
allergy to local anaesthetics and cases where we were unable
to communicate appropriately with the patient for psychologi-
cal reasons or for language difficulties. Further, we did not
include patients with septic arthritis, haemarthrosis, joint
trauma or mechanical joint complications.
Methods
All arthroscopies were performed in the same procedure
room, designated for this and other small operative proce-
dures requiring sterility and situated at our outpatient clinic.
During most procedures three or more persons were involved;
one or two operators (one teaching), one nurse and one
assistant nurse (not in sterile dressing) taking care of tissue
samples. Rod-lens arthroscopes (Karl Storz Gmbh, Tuttlingen,
Germany) of three different dimensions (1.9 mm for proximal
interphalangeal, metacarpophalangeal, wrist and elbow joints;
2.4 mm for shoulder, ankle and knee joints, and 4.0 mm for
knee joints), all with a 30° angle, were used throughout. Spoon
forceps (Karl Storz Gmbh, Tuttlingen, Germany) of different
sizes were used to obtain the biopsies, the largest with a diam-
eter of 3.5 mm, was used in knee joints. To minimise the
effects of the procedure on the macroscopic appearance of
the SM including circulation, no tourniquet was used, anaes-
thetic drug (xylocain) was used without adrenaline and maxi-
mum water pressure was put at 50 cm (for irrigation fluid). All
arthroscopies were performed in accordance with the Helsinki
Declaration, and where appropriate, ethical permission was
given by the ethical committee at the Karolinska Institute, and
written consent given by each patient before entering study.
Biopsies were put in cryotubes (Simport Plastics, Quebec,
Canada) and frozen in precooled (-70°C) isopentane within
two minutes (most often within one minute) after removal. They
were stored until sectioned in -70°C. Before sectioning, biop-
sies were embedded in Tissue-Tek®  O.C.T. Compound
(Sakura Finetek USA Inc, Torrance, California, USA). All biop-
sies were cut in -20°C (cryostat setting; 7 μm) and stained
with H&E in a standard procedure. The sections were evalu-
ated for adequate histology (inflammation and not subsynovial
or fibrotic tissue) before further stainings were performed.
The arthroscopic procedure of the knee joint is detailed below,
and is principally the same for other joints. The joint is exam-
ined from the outside for signs of inflammation (pain, swelling
and hypertrophy of the joint capsule). Two entry portals are
then localised (infralateral, supralateral and/or supramedial
portals) and anaesthetised using 10 to 15 ml of xylocaine 10
mg/ml without adrenaline for skin and joint capsule. Disinfec-
tion and draping of the leg occurs. A minimal skin incision is
made with a scalpel (<5 mm) for portals. The arthroscope por-
tal and trocar are introduced and excessive synovial fluid is
extracted and stored. The trocar is replaced by the arthro-
scope, and 10 ml of xylocaine is added in to the joint as it is
filled with physiological saline for clear vision. The synovium is
inspected systematically (suprapatellar pouch, lateral and
medial recesses and gutters, leaving the tibiofemoral joint and
posterior cavity of the joint). Water pressure is kept below 30
cm, so as not to interfere with vascularity. Biopsy sites are cho-
sen according to maximal macroscopic inflammation and ana-
tomical site (preferably three sites; one close to the cartilage-
pannus-junction and two further away), and photographed.
The second portal for the biopsy forceps is then introduced.
Synovial biopsies are retrieved, six to eight from each site, 12
to 24 per joint in total. Care is taken not to sample too deeply
(subsynovial fat or capsule). Maximum time from biopsy sam-
pling to freezing is set at two minutes, but is usually within 30
to 40 seconds. Joint lavage, to remove blood and debris, is
used when needed for visuality throughout the procedure, but
kept at a minimum so as not to interfere with treatment effect
for drug evaluation (usually 300 to 600 ml, and never more
than 1000 ml). Excessive fluid is extracted from the joint via
both portals and intraarticular steroids are introduced via the
arthroscope if indicated. Portals are removed, wounds
cleaned, dried and taped with sterile strips then covered with
sterile waterproof dressing. Immediately after the arthroscopy
the operator maps the biopsy sites, as well as areas of
increased vascularity, hypertrophy (granulations and villi) and
fibrosis [36]. The map (Figure 1), together with the photo-Available online http://arthritis-research.com/content/11/3/R81
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graphs taken, makes it possible to resample in close proximity
to the primary site during consecutive procedures. The map
and photos also allow retrospective analysis of biopsy sites
and activity.
The entire procedure normally takes 40 to 60 minutes, and
because only local anaesthetics and no sedation is used, the
patient is able to walk immediately after the procedure. Before
leaving the clinic, the patient is informed to avoid water contact
on the wounds for two days. In order to quantitate possible
complications and help patients after the procedure, the
patient is contacted by the rheumatologist who performed the
arthroscopy within the next few days. The occurrence of any
complications is registered immediately after the arthroscopic
procedure, at the following telephone contact and at consec-
utive contacts with the patients.
Creation and evaluation of a macroscopic scoring 
system
Eight representative video printer photographs, taken at knee
joint arthroscopy procedures, were chosen by one of the
authors (EaK) to illustrate various features of macroscopic syn-
ovitis and serve as reference images. Scoring was made by
EaK in relation to three parameters; hypertrophy, vascularity
and synovitis. For each parameter a five point scale (0 to 4)
was used.
Seven raters (rater 1 to rater 7) with different experience in
arthroscopy were asked to score 50 different joint images that
had been selected by EaK, after the scale had been described
to each rater by EaK. The order of reading was randomised.
All scores were collected and inter-individual variation regis-
tered. Images that produced very variable scores were re-eval-
uated during a joint session. The eight reference image scores
used were revised together. Ten new images were scored by
all observers individually. These scores were compared, and a
reference score was decided for each of these images.
From the experience gained in this study we prepared instruc-
tions for macroscopic scoring including characterised arthro-
scopic images, the 'Macro-score' [see Additional data files 1
and 2]. A new set of 50 images were scored by all raters at two
occasions, with a minimum of 24 hours in between. The
scores were analysed by descriptive analysis, including intra-
and inter-rater variability and median scores.
Five control-raters with no previous experience of arthroscopy
scored the same set of 50 images. They did not receive any
further instructions than the Macro-score written instructions.
Control-rater scores were analysed by descriptive statistics,
including inter-rater variability and comparison to the median
scores.
Results
Evaluation of the arthroscopic procedure for feasibility, 
complications and for yield of biopsies suitable for 
analysis
During seven years we performed 408 arthroscopic proce-
dures in 237 patients (Tables 1 and 2 for patient characteris-
tics). Tow out of three of the patients were classified as RA,
fulfilling the American College of Rheumatology criteria [52].
The mean disease duration was 7.5 years (median 4 years)
and 32% had disease duration less than one year. The mean
arthritis duration was 43 weeks (median 12 weeks) and 72%
were women. The maximum number of arthroscopies per-
formed in one patient was four (six patients). The procedure
itself typically lasted 40 to 60 minutes, with the most time
required for preparation (disinfection, anaesthesia, draping
etc). In a limited number of procedures (n = 38) only the oper-
ator and the assistant nurse were involved, showing the feasi-
bility of this simplified approach.
Figure 1
Arthroscopy map of the knee joints Arthroscopy map of the knee joints. The patella is folded sideways. Areas of hypertrophy (villi, granulations) are marked as indicated, areas of 
increased vascularity are encircled and biopsy sites are mapped immediately following each procedure by the performing arthroscopist. Dx, right 
side of patient; SIN, left side of patient.Arthritis Research & Therapy    Vol 11 No 3    af Klint et al.
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Except for two patients presenting with haemarthrosis three
days and two weeks after the arthroscopy, respectively, no
major complications were seen including deep vein thrombo-
sis. A minor complication was one wound infection six weeks
after arthroscopy at the supralateral portal where the patient
had not removed the surgical strips. Intraarticular bleeding
during the procedure could complicate biopsy sampling due
to loss of vision, especially in small joints. However, in all of
these cases bleeding stopped during or soon after the proce-
dure. Pain in the investigated or other joint occurred in a small
number of patients and in 12 (3%) cases pain restricted the
procedure so that no or fewer biopsies were taken than were
originally planned. In one patient pain was considered severe
two weeks after the procedure. Additional medical treatment
was received and the pain subsided slowly. In one patient the
joint was not extending due to an inability to relax, requiring the
arthroscopy to be terminated. In 18 procedures (11 knee
joints and 7 small or medium-sized joints) we abstained from
biopsies as no active synovitis could be visualised. In these
cases synovium was either normal or fibrotic as assessed
macroscopically. No patient had to stay at the hospital for
more than one hour after the procedure, and no long-term
complications were seen.
For knee arthroscopies, 97% of procedures were conducted
as planned, and 95% of retrieved tissue was appropriate for
histology, resulting in a total yield of 92% (Table 3). For smaller
joints the quality of the biopsies was less consistent, resulting
in 86% of the arthroscopies to be conducted as planned, with
40% of the retrieved tissue being appropriate for histology,
resulting in a total yield of appropriate biopsy material of 34%.
The major reason for this low yield in small joints was the diffi-
Table 1
Patient characteristics at time of arthroscopy
Number of procedures 408
Number of patients 237
Age (mean) 52 years (range 20 to 85)
Sex 170 women/67 men
Disease duration (mean) 91 months (range 1 to 623)
Arthritis duration (mean) 43.5 weeks (range 0 to 564)
Patients on NSAIDs at arthroscopy 148
Patients on DMARDs at arthroscopy 99 (88 on methotrexate)
DMARDs = disease-modifying anti-rheumatic drugs; NSAIDs = non-
steroidal anti-inflammatory drugs.
Table 2
Diagnosis at time of arthroscopy
Diagnosis All patients (n) RF+
(n)
Patients with early disease (<12 months) (n) RF+
(n)
Rheumatoid arthritis 160 129 52 39
Undifferentiated monoarhtritis 13 4/11a 8b 2/6a
Undifferentiated oligoarthritis 9 2 4b 1
Undifferentiated polyarthritis 7 2 5c 1
Juvenile idiopathic arthritis 9 4 0 0
Adult Still's disease 1 0 0 0
Undifferentiated spondylarthritis 4 0 2 0
Psoriatic arthritis 12 0 2 0
Ankylosing spondylitis 1 0 0 0
Ulcerative colitis 2 0/1d 10
Undifferentiated systemic inflammatory disease with arthritis 1 0 0 0
Systemic lupus erythematosus 3 0 1 0
Cutaneous PAN with arthritis 1 0 0 0
Osteoarthritis 4 4 1 1
Healthy individuals 10 ND NA NA
Sum 237 141 76 42
All patients had clinically active inflammation or pain in at least the investigated joint (exceptions: healthy individuals). a Two patients were not 
tested for RF. b One RF+ patient later fulfilled RA classification criteria. c One RF-patient later fulfilled RA classification criteria, one RF-patient was 
later diagnosed positive for human parvovirus type B19 infection and one RF+ patient was later diagnosed with dermatomyositis. d One patient 
was not tested for RF.
NA = not applicable; ND = not determined; PAN = polyarteritis nodosa; RF = rheumatoid factor.Available online http://arthritis-research.com/content/11/3/R81
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culty in obtaining appropriate vision within the joint, which led
to a practically blind biopsy in many cases.
Creation and evaluation of a method for macroscopic 
scoring of synovitis during arthroscopy
We used printed photographs of synovitis obtained at arthros-
copy in order to evaluate a scoring system that represents a
development of a previous scoring procedure [36]. In order to
quantitate how individual scorings may differ between different
potential arthroscopists, we asked seven raters to assess 50
images. After following the steps outlined above, we analysed
a second set of 50 images for intra- and inter-rater variation.
Seven raters individually scored 50 images twice (with a mini-
mum of 24 hours in between) for the three parameters, pro-
ducing a total of 2100 individual scores (700 scores per
parameter, 300 scores per rater and 14 scores per image and
parameter). Median scores were calculated for all 50 images
(Figure 2). Most images scored 1 and 2 in a five point scale (0
to 4, 0 representing no activity and 4 representing maximum
activity) indicating low to medium levels of activity. No image
rated a maximum median score of 4 for synovitis. More images
had median scores of 0 for vascularity and synovitis compared
with hypertrophy, indicating fibrotic inactive tissue. Some of
these images and scores were used to create the written set
of instructions called the Macro-score [see Additional data
files 1 and 2].
Intra-rater variation
Intra-rater variation was calculated from all 2100 scores. For
hypertrophy 347 of 350 scores (99.1%) scored within one
scoring step at the second rating session. For vascularity and
synovitis the percentages were 98.9 and 99.1, respectively,
showing a very low intra-individual variation. Each rater pro-
duced 150 scores, seven images yielded a scoring difference
of more than one by one rater, the rest producing a maximum
of one point in scoring difference. A mean perfect match
(same score twice by the same rater) for hypertrophy was
71%, for vascularity 69% and for synovitis 71% (Figure 3a).
When each parameter was analysed per score (Figure 3b), we
could see that the best reproducibility was seen at the end
points of each index. We could see a drift in consistency (Fig-
ure 3c), even though all raters calibrated themselves accord-
ing to the jointly scored image set immediately before each
scoring session.
Inter-rater variation
Inter-rater variation was calculated from the first set of scores
by each rater, in all 1050 scores. Of 1050 individual scores,
1036 (98.7%) had an absolute deviation of one point or less
from the median score. The deviation from the median varied
between raters (Figure 4a); three raters averaged 100%, one
rater averaged 99% and two raters averaged 97% of scores
deviating by one point or less from the median, respectively,
resulting in a mean of 99% of scores within one point of the
median. We also analysed inter-rater variation by calculating
Table 3
Approved histology per joint
Joint Shoulder Elbow Wrist MCP PIP Right knee Left knee Ankle Sum
Procedures (n) 2 7 38 24 3 181 142 11 408
Biopsies approved by histology (%) 0 75 26 25 100 94 94 83 83
MCP = metacarpophalangeal; PIP = proximal interphalangeal.
Figure 2
Median scores Median scores. Scores (%) sorted by median. Fifty images were scored for three parameters twice by seven raters, producing a total of 2100 
scores. For S no images had a maximum median score of 4. H = hypertrophy; S = synovitis; V = vascularity.Arthritis Research & Therapy    Vol 11 No 3    af Klint et al.
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Figure 3
Intra-rater variation Intra-rater variation. (a) Percentage of perfect matches (score 1 = score 2) for individual raters. (b) Percentage of perfect matches (score 1 = score 
2) at different scoring levels. (c) Rater consistency (sum of score 2 minus score 1). 0 indicates a high consistency between scoring sessions. A pos-
itive value indicates an increase in scores at the second scoring session. A negative value indicates a decrease in scores at the second scoring ses-
sion.Available online http://arthritis-research.com/content/11/3/R81
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the range of scores for each image parameter, given by the
seven raters (Figure 4b). Range was two points or less in 139
(92.7%) of 150 image scores. This analysis shows that most
scores were indeed close to one another and that raters were
in close agreement (+/- one point) for almost all images.
Comparison of control-rater scores to median scores of 
raters 1 to 7
The same set of 50 images that were scored by raters 1 to 7,
were scored by five control-raters (rater A to E) not experi-
enced in arthroscopy using the Macro-score [see Additional
data files 1 and 2], producing 150 scores per rater, 650
scores in total. Average individual perfect matches (scores of
control-raters equal to median scores of raters 1 to 7) varied
between 41% and 56%. Perfect matches of median scores of
raters A to E and 1 to 7 gave the best results (Figure 5a), 58%
for each parameter, indicating that no individual parameter
was harder to score. We also calculated percentage of scores
with an absolute deviation of one point or less from the median
score of raters 1 to 7. This turned out to be very high, between
82% and 100%. The average for each control-rater was
between 90% and 96%. The median of the control-raters that
were within one point of the median for raters 1 to 7 was even
better; between 96% and 100%, giving an average of more
than 97% of median scores within one point of the median by
raters 1 to 7.
Discussion
Arthroscopy in the hands of the orthopaedic surgeons is con-
sidered a safe and reliable method. In the surveys by Small
[53] and Sherman and colleagues [54] the complication rate
was between 2 and 5%. The feasibility and safety of arthros-
copy in the hands of rheumatologists have been described in
several reports over recent years; Kane and colleagues [55]
identified 36 rheumatology centres in Europe, the USA and
Australia that performed arthroscopy for clinical and research
Figure 4
Inter-rater variation Inter-rater variation. (a) Distance to the median. Percentage of scores (from the first rating session) with an absolute distance from the median of one 
point or less. (b) Score range in percentage of total scores. A range of 0 is a perfect match of all seven scores for an image (seven raters). A range 
of one means that all scores are within two values. H = hypertrophy; S = synovitis; V = vascularity.Arthritis Research & Therapy    Vol 11 No 3    af Klint et al.
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purposes. In this survey as well as in reports from individual
centres (Table 4) few complications have been reported
(1.5%). It is therefore comforting that complications seen in
our series are at a low level (0.7%). Haemarthrosis was the
most common major complication both from the survey
(0.9%), as well as in our study (two patients or 0.5%). Impor-
tantly, other major complications, such as joint infection or
deep vein thrombosis, did not occur at all in our study. In pre-
vious studies joint infections have been observed and been
associated with irrigation volume [55], possibly as a marker of
the length of the procedure. In our series, no procedure lasted
for more than one hour, and we kept lavage volume at a mini-
mum, which might thus contribute to lowering the risk of infec-
tion. The use of arthroscopy without tourniquet probably also
reduces the risk of thrombosis or thrombophlebitis. In 111 pro-
cedures intraarticular steroids were administered in the exam-
ined joint at the end of the procedure, with no increased risk
of adverse events.
Despite the use of local anaesthesia, pain may still be a prob-
lem. In a study of 50 patients [56] pain was reported in 50%
during the procedure, and in 67% postoperatively. In that
study, the best results for pain were seen in those who had
femoral nerve blocks (most had no pain, and none had moder-
ate or severe pain during or after the procedure) as opposed
to local anaesthesia (none reported no pain during the proce-
dure, severe pain was reported in 14% during and 10% after
the procedure). Despite this only one patient declined to have
a future second arthroscopy. In our study all received local
anaesthesia. Occurrence of pain was notified in each case by
the physician responsible for the procedure, but not captured
in a formal protocol; we had to prematurely terminate the pro-
cedure in 3% of cases due to pain during the procedure. Only
in one patient was there a severe pain that lasted for two
weeks after the procedure. Also, the large majority of patients
who were asked to a second arthroscopy consented to this
procedure, indicating that the subjective experience of pain
was not high. For future arthroscopic investigations, however,
we advise that formal protocols for measurement of pain are
introduced.
The yield of biopsies was highly satisfactory from the proce-
dures directed towards the knee joints (94%) and acceptable
from ankles joints (83%). The yield from small joints was, how-
ever, only 34%. This may be an obstacle that is possible to
overcome as other groups have reported higher success rates
for small joints including metacarpophalangeal joints [57]. As
we were not able to reach this level of success, we draw the
conclusion that sampling small joints requires special skills
and training programs, and that new investigators should be
aware of the difficulties. In our case, we decided to restrict the
studies mainly to knees in studies where repeated biopsy sam-
pling of the same joint was required [46-48,50,51].
In polyarticular arthritis patients a high degree of clinical inter-
articular variation of inflammation between different joints is
clinically well recognised. This variation also occurs within the
macroscopic and microscopic patterns of the synovium in the
individual joint [36,39,58-64]. Some studies point to the cor-
relation of macro and microscopic features [12,36,65-67],
while others support that variation is limited [59,60,64,68,69].
To cope with this issue four main principles of sampling the
synovium in large joints like the knee have been described:
sampling predetermined sites [12]; sampling according to
macroscopic signs of inflammation [36]; sampling predeter-
mined sites and according to macroscopic signs of inflamma-
tion [65]; and sampling a limited number of predetermined
sites to represent the whole joint [58,60,68]. Some studies
point to the cartilage pannus junction [36,70,71] as the site of
most active inflammation, although not in all aspects [72]
implying the special significance of this region. Against this
Figure 5
Control-rater variation (%) Control-rater variation (%). (a) Perfect matches (score of raters A to E 
= median score of raters 1 to 7). *Median score of raters A to E = 
median score of raters 1 to 7. (b) Distance to the median. Scores of 
raters A to E with an absolute distance from the median of raters 1 to 7 
of one point or less (compare with Figure 4a). *Median scores of raters 
A to E with an absolute distance from the median of raters 1 to 7 of one 
point or less. H = hypertrophy; S = synovitis; V = vascularity.Available online http://arthritis-research.com/content/11/3/R81
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background, we have chosen to sample tissues based on max-
imum macroscopic inflammation far from and close to carti-
lage. When performing consecutive studies with repeated
procedures, we prioritised sampling of the biopsies close to
the same sites as the first. Samples from the same site are
then compared for longitudinal outcome comparisons. To aid
in this effort, we have made a simplified map of the knee joint
(Figure 1) where macroscopic characteristics and biopsy sites
are marked. Each site is also photographically documented by
the arthroscope, now digitally stored as opposed to earlier
video printer photographs.
There is an obvious need to correlate macroscopic findings
and microscopic/molecular analysis of inflamed joints. Several
different macroscopic scales have been used [36,65,73] and
have been found to correlate with other SM features
[12,36,65-67,74,75]. Notably few studies have been pub-
lished on intra and inter-variation of different raters in macro-
scopic scoring. This issue was addressed by Reece and
colleagues [76] using 44 video recordings of the arthroscopic
procedure. Three observers reached good correlation for vil-
lous formations, the most pronounced form of hypertrophy, in
RA; however, the results were not as good in spondylarthritis
patients. Granulations and capillary hyperaemia were not reli-
able in this study. This is interesting as in the study by Lindblad
and Hedfors [36], hyperaemia was the most important feature
corresponding to microscopic changes, as also noted by oral
surgeons [77]. Before reliable correlations can be made
between macro and microscopic scoring systems these
parameters need to be studied more extensively. This was one
reason for undertaking this study.
In our study we chose not only to score global synovitis, but
also to individually measure its main features; hypertrophy and
vascularity. Hyperaemia was not included as an individual
parameter due to its intrinsic variation physiologically as well
as observationally. However, hyperaemia was included in the
global synovitis score, in which all observed features of inflam-
mation were included. Thus the score adds more information
to the history of the synovitis as a global synovitis score of 0 is
not always normal, but also includes previously active fibrotic
changes scored as hypertrophy. This score set can be used
for scoring entire joints where a video perhaps would be of
greater value, but our aim was primarily to get low intra and
inter-rater score variation in scoring biopsy sites for research
purposes. In this study we report that intra-individual scoring
variation was low; at the second scoring 99% of all scores
were within one point of the first scores using a five-point
scale. Further, a perfect match between first and second scor-
ing sessions was reached in 70% of scores, and no single
parameter had a substantially greater intrinsic variability. We
also showed low inter-rater variation: 1036 of 1050 individual
scores (98.7%) were within one point from the median score.
The range was two points or less in 139 of 150 (92.7%) image
scores. These numbers could presumably be improved with
further training.
We also constructed an easy to use set of instructions for
macroscopic evaluation, the Macro-score [see Additional data
files 1 and 2]. These written instructions were tested on the
same set of 50 photographs by five control-raters with no pre-
vious experience of arthroscopy. Without any other directions
they scored well; between 41% and 56% of individual scores
were equal to the median scores of the raters from the first
Table 4
Complications of arthroscopy
First author AS (n) Major (%) Minor (%) Haemarthrosis (%) Joint infection (%)
Sherman and colleagues [54]‡ 2640 126 (4.8) 97 (3.7) (2.0) (<0.5)
Small [53]‡ 10262 (1.7) 104 (1.0) 21 (0.2)
Szachnowski and colleagues [78] 335 (1.2) (12.8) nd nd
Kuzmanova and colleagues [79] 206 4 (2.0) 15 (7.5)* 7 (3.5) 1 (0.5)
Reece and colleagues [80] 278 1 (0.4) 13 (4.7) 0 1
Wollaston and colleagues [81] 342 1 (0.3) 5 (1.5) 0 0
Smith and colleagues [56] 128 nd (studied pain in conjunction with AS)
Baeten and colleagues [73] 150 0 (<10) 0 0
Gerlag and Tak [82] >2000 <0.3
Kane and colleagues [55] 16532 237 (1.5) 141 (0.9) 16 (0.1)
af Klint (present study) 408 2 (0.5) 1 (0.2) 2 (0.5) 0
‡ Survey of orthopaedic AS. *Haemarthrosis was regarded as a minor complication. Survey of AS.
AS = arthroscopy; nd = not determined.Arthritis Research & Therapy    Vol 11 No 3    af Klint et al.
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group, and between 82% and 100% of scores were not more
than one point from the median. The time to understand the
score and score 50 images was about 2 to 2.5 hours, sug-
gesting that the Macro-score is reliable and easy to use.
A weakness in this study was the lack of maximal inflammation
scores. We presume that this is due to the population studied
– we only included chronic polyarthritis patients, and no acute
forms such as septic arthritis or gout. Given the clinical activity
in these forms of arthritis, we would probably see more active
synovitis in such images. At the other end of the spectrum we
had a number of images depicting no inflammation, also from
healthy individuals serving as controls. Interestingly, also
healthy individuals with no history of joint problems could be
seen to have minor inflammatory changes, in line with our ear-
lier experience [41].
Conclusions
It is our experience that rheumatological arthroscopy is a safe
method with very few complications. For knee joints it is a reli-
able method to retrieve representative tissue in clinical longitu-
dinal studies. We also created an easy to use macroscopic
score that needs to be validated against other methodologies,
which we hope will be of value in further developing interna-
tional standards in this area.
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